Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma
Abstract
TERT promoter mutations are observed in 80% of wild-type IDH glioblastoma (GBM). Moreover, the upstream TERT transcription factor GABPB1 was recently identified as a cancer-specific therapeutic target for tumors harboring a TERT promoter mutation. In that context, noninvasive imaging biomarkers are needed for the detection of TERT modulation.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 23, 2022
- Source ID
- 10.1093/neuonc/noac112
Entities
People
- Anne Marie Gillespie
- Carter J. Barger
- Chibo Hong
- Donghyun Hong
- Georgios Batsios
- Joseph F. Costello
- Lee Chen
- Marina Radoul
- Nicholas Stevers
- Noriaki Minami
- Pavithra Viswanath
- Russel O Pieper
- Sabrina M. Ronen
- Yaewon Kim
Organizations
- National Institutes of Health
- United States Department of Defense
- University of California, San Francisco